Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
57%(4 trials)
Terminated
2(22%)

Phase Distribution

Ph early_phase_1
1
11%
Ph phase_2
5
56%
Ph phase_3
1
11%
Ph phase_1
2
22%

Phase Distribution

3

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 12 (22.2%)
Phase 25 (55.6%)
Phase 31 (11.1%)

Trials by Status

completed778%
terminated222%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_3

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

NCT03151408
terminatedphase_2

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

NCT03151304
completedphase_2

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01912274
completedphase_1

A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body

NCT03495934
completedphase_2

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

NCT02267278
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03151408Phase 3

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Terminated
NCT03151304Phase 2

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Terminated
NCT01912274Phase 2

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Completed
NCT03495934Phase 1

A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body

Completed
NCT02267278Phase 2

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Completed
NCT01873703Phase 2

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Completed
NCT01993641Phase 2

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Completed
NCT02058784Early Phase 1

Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects

Completed
NCT02118909Phase 1

Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9